selective CSF1R kinase inhibitor
oral, 30 mg BIW, phase III, cancer
from structure-based design
Molecular Cancer Therapeutics
Deciphera Pharmaceuticals
vimseltinib
The Deciphera CSF1R kinase inhibitor, vimseltinib (DCC-3014), is a selective oral TKI that induces an inactive conformation of CSF1R by biomimetically nucleating an array of 17 H-bonds in the switch control…